Shah, Amishi Y.

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 1,791

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., et al. (2020) · Nature Medicine

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 318

Belzutifan efficacy and tolerability in patients with sporadic metastatic clear cell renal cell carcinoma

Wang, E., Rupe, E. S., Mukhida, S. S., Johns, A. C., Campbell, M. T., Shah, A. Y., Zurita, A. J., Gao, J., Goswami, S., Jonasch, E., et al. (2025) · European Urology Focus

Renal cell carcinoma treatmentFerroptosis and cancer prognosis

Cited by 4